HOME >> BIOLOGY >> NEWS
Amid growing public concerns, bioscience firms begin formalizing ethical decision-making practices

Pharmaceutical, biotechnology and bio-agricultural companies, grappling with an array of complex ethical issues, are gradually formalizing systematic approaches to ethical decision-making, according to a two-year study by leading international ethics and bioscience researchers.

Bioscience companies operations pose many ethical dilemmas. They produce and sell genetically modified foods, conduct gene therapy experiments and embryonic stem cell research to produce new therapies, use animals to test new pharmaceuticals, manipulate life'TMs building blocks, create transgenic animals to produce drugs, commercialize genetic and biological materials, compile and use personal genetic information, and set drug prices for domestic and developing country markets.

Companies of all sizes and in all sectors, faced with growing questions and concerns, are recognizing and acting on public pressure to demonstrate business methods that are not just legal but ethical too, according to research conducted jointly by the Joint Centre for Bioethics (JCB) at the University of Toronto, the Keck Graduate Institute of Applied Life Sciences (Claremont CA), Stanford University (Palo Alto, CA), and l'TMUniversite de Montreal.

More than 100 in-depth interviews with managers and top executives at 13 diverse bioscience firms, large and small, all with reputations for developing new approaches, were conducted to capture and summarize the way the industry innovators today address ethical challenges. The research represents some of the first empirical evidence of how bioscience companies are dealing with ethical issues now, establishing a constructive starting point on which to build.

The research results are newly published in the book Bioindustry Ethics (Elsevier Academic Press), with a summary (and accompanying editorial) published today by PLOS Medicine, the paper entitled "Lessons on Ethical Decision Making fro
'"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
University of Toronto Joint Center for Bioethics
3-Apr-2006


Page: 1 2 3 4 5

Related biology news :

1. Citrus greening continues to spread in citrus growing areas
2. Threats to wild tigers growing
3. FSU engineering professor growing bone in a lab
4. Use of wind energy in US growing, but planning and guidelines are lacking
5. MIT creates 3-D scaffold for growing stem cells
6. A new approach to growing heart muscle
7. A giant among minnows: Giant danio can keep growing
8. After North Korea test, what can be done to reduce the growing nuclear threat?
9. Genomatix appoints distributor for the growing Chinese market
10. Minimal cocktail for growing human embryonic stem cells established
11. New journal article urges use of animal serum-free media for growing live cells

Post Your Comments:
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/19/2014)... -- Decision Resources Group finds that the Asia ... through 2023 as the aging population, increasing adoption of ... all spur procedure volumes. Growth will be particularly rapid ... and India , where rising ... a larger proportion of the population. Other ...
(Date:12/17/2014)... NY (PRWEB) December 16, 2014 The ... changes since 2013, which is why IBISWorld updated its ... industry continues to benefit from an intensified focus on ... proposal for new emission standards for power plants and ... operators. According to IBISWorld Industry Analyst Sarah Kahn, “a ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
Cached News: